Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis

Journal of Dermatological Science

Volumn 71, Issue 1, 2013, Pages 29-36

  Schaper, Katrin ^a   Dickhaut, Jeannette ^b   Japtok, Lukasz ^c   Kietzmann, Manfred ^a   Mischke, Reinhard ^a   Kleuser, Burkhard ^c   Bäumer, Wolfgang ^a,d  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Imiquimod; Psoriasis; SCID mice; Sphingosine 1 phosphate

Indexed keywords

CALCIPOTRIOL; DIFLORASONE DIACETATE; FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; SKIN EDEMA; SKINFOLD THICKNESS;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; CELL DIFFERENTIATION; CELL PROLIFERATION; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KERATINOCYTES; LOCAL LYMPH NODE ASSAY; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED BALB C; MICE, SCID; PROPYLENE GLYCOLS; PSORIASIS; RECEPTORS, LYSOSPHINGOLIPID; SKIN; SKIN TRANSPLANTATION; SPHINGOSINE; TIME FACTORS;

EID: 84879028625     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.03.006     Document Type: Article

References (33)

1. von Wenckstern H., Zimmermann K., Kleuser B. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. Arch Immunol Ther Exp 2006, 54:239-251.
2. Manggau M., Kim D.S., Ruwisch L., Vogler R., Korting H.C., Schafer-Korting M., et al. 1Alpha, 25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001, 117:1241-1249.
3. Vogler R., Sauer B., Kim D.S., Schafer-Korting M., Kleuser B. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J Invest Dermatol 2003, 120:693-700.
4. Schuppel M., Kurschner U., Kleuser U., Schafer-Korting M., Kleuser B. Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype. J Invest Dermatol 2008, 128:1747-1756.
5. 2+ signaling. J Dermatol Sci 2008, 51:89-102.
6. Gollmann G., Neuwirt H., Tripp C.H., Mueller H., Konwalinka G., Heufler C., et al. Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. Int Immunol 2008, 20:911-923.
7. Reines I., Kietzmann M., Mischke R., Tschernig T., Luth A., Kleuser B., et al. Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J Invest Dermatol 2009, 129:1954-1962.
8. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
9. Nickoloff B.J., Qin J.Z., Nestle F.O. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007, 33:45-56.
10. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
11. Murphy G., Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol 2011, 25(Suppl. 4):3-8.
12. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
13. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. New Engl J Med 2012, 366:1190-1199.
14. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
15. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
16. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
17. Boehncke W.H., Ochsendorf F.R., Noll S., Urban M., Popp A., Waldherr D., et al. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol 2005, 153:758-766.
18. Bosman B., Matthiesen T., Hess V., Friderichs E. A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. Skin Pharmacol 1992, 5:41-48.
19. Blot V., Jaquemard U., Reissig H.U., Kleuser B. Practical synthesis of sphingosine-1-phosphate and analogues. Synthesis (Stuttgart) 2009, 5:759-766.
20. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
21. Boehncke W.H., Sterry W., Hainzl A., Scheffold W., Kaufmann R. Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. Arch Dermatol Res 1994, 286:325-330.
22. Herzinger T., Kleuser B., Schafer-Korting M., Korting H.C. Sphingosine-1-phosphate signaling and the skin. Am J Clin Dermatol 2007, 8:329-336.
23. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002, 277:21453-21457.
24. Tung D., Cheung P.H., Kaur P., Foreman O., Kavirayani A., Hain H.S., et al. Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology 2011, 88:100-113.
25. Czeloth N., Bernhardt G., Hofmann F., Genth H., Forster R. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J Immunol 2005, 175:2960-2967.
26. Piskin G., Sylva-Steenland R.M., Bos J.D., Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176:1908-1915.
27. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130.
28. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
29. Liao J.J., Huang M.C., Goetzl E.J. Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol 2007, 178:5425-5428.
30. Roark C.L., French J.D., Taylor M.A., Bendele A.M., Born W.K., O'Brien R.L. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. J Immunol 2007, 179:5576-5583.
31. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
32. Passos S.T., Silver J.S., O'Hara A.C., Sehy D., Stumhofer J.S., Hunter C.A. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol 2010, 184:1776-1783.
33. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (New York, NY) 2002, 296:346-349.